Paper reports that Gritstone’s tumor-specific, neoantigen vaccination approach drives priming and boosting of tumor-specific T cells, including cytotoxic CD8+ T cells T cells linked to molecular responses in advanced colorectal cancer (CRC) patients and associated with extended overall survival, which has been observed in follow-up to the Phase 1/2 study GRANITE now in a randomized, controlled Phase 2/3 trial in newly diagnosed metastatic, microsatellite-stable colorectal can